BMJ Mental Health, published by the esteemed BMJ PUBLISHING GROUP, is a pioneering open-access journal dedicated to advancing research and knowledge in the field of Psychiatry and Mental Health. Launched in 2023, this journal has rapidly established itself within the academic community, achieving a prestigious Q1 ranking and a ranking of #123 out of 567 in its category, placing it in the 78th percentile according to Scopus. With its base in the United Kingdom, the journal aims to foster impactful research through its commitment to accessibility, allowing professionals, researchers, and students alike to engage with high-quality content freely. The E-ISSN: 2755-9734 enables seamless digital access to cutting-edge studies, reviews, and perspectives that address the complexities of mental health, thereby paving the way for better practices and innovations in mental health care. Join a community of dedicated scholars and practitioners in reshaping the landscape of mental health research with BMJ Mental Health.

Substance Abuse: Research and Treatment is a premier open-access journal published by SAGE Publications Ltd, focusing on the multifaceted aspects of substance use and its impact on mental health. Since its establishment in 2008, this journal has been dedicated to disseminating innovative research findings, case studies, and reviews that enhance understanding and treatment of substance-related disorders. With an impact factor that reflects its standing in the field, currently ranked in the Q2 category of Psychiatry and Mental Health, Substance Abuse: Research and Treatment strives to foster interdisciplinary dialogue among researchers, practitioners, and students. By making its content freely accessible, the journal encourages widespread engagement and application of evidence-based practices to mitigate substance abuse issues. The journal’s diverse global perspectives make it a vital resource for anyone invested in advancing knowledge and improving treatment outcomes in this critical area of public health.

Rivista di Psichiatria, published by PENSIERO SCIENTIFICO EDITORE, stands as a significant contributor to the field of Psychiatry and Mental Health since its inception in 1975. With an ISSN of 0035-6484 and an E-ISSN of 2038-2502, this esteemed journal offers a platform for rigorous academic discourse and cutting-edge research, helping to shape contemporary psychiatric practices and theories. Currently holding a Q2 designation in Psychiatry and Mental Health based on the 2023 category quartiles, and ranking #197 out of 567 in Scopus, it reflects a commendable 65th percentile among its peers. The journal welcomes contributions that encompass a broad range of topics related to mental health, encouraging contributions from a multidisciplinary approach, which aids in its goal of advancing the understanding and application of psychiatric science. While it is a traditional journal without Open Access options, access to its valuable content can support researchers, clinicians, and students in their pursuit of knowledge and innovation within the field. Situated in Rome, Italy, at VIA SAN GIOVANNI VALDARNO 8, ROME 00138, the journal continues to enhance its rich legacy, promoting the exchange of ideas and fostering collaboration amongst practitioners and scholars alike.

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.

Journal of Psychopathology, published by PACINI EDITORE, is a pivotal academic resource in the realms of clinical psychology and psychiatry. With an ISSN of 1592-1107 for print and 2499-6904 for electronic formats, this journal has been a significant platform for scholarly discourse since its inception in 2001, continuing through to 2024. Situated in Pisa, Italy, it is recognized for its rigorous academic standards, as evidenced by its Q3 ranking in both Clinical Psychology and Psychiatry and Mental Health categories as of 2023. The journal focuses on publishing high-quality research articles, reviews, and case studies that contribute to a comprehensive understanding of psychopathological issues. Although not open access, the journal promotes accessibility through various institutional subscriptions, ensuring wide dissemination of valuable insights. With significant Scopus rankings—177 out of 311 in Clinical Psychology and 360 out of 567 in Psychiatry and Mental Health—the journal is essential for researchers, practitioners, and students dedicated to advancing knowledge and practices in mental health.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a pivotal peer-reviewed journal in the fields of pharmacology and psychiatry. Established in 1986, it has garnered a prominent reputation with a 2023 impact factor placing it in the Q2 category for both Pharmacology and Psychiatry and Mental Health. With an impressive Scopus ranking of #227 in the Psychiatry and Mental Health category and #114 in Pharmacology, it serves as an essential platform for researchers seeking to disseminate critical findings on psychopharmacological interventions and their clinical efficacy. The journal’s rigorous peer-review process ensures that only high-quality research is published, making it a trusted resource for professionals and students alike. By focusing on the latest advancements and evidence-based practices, the INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY contributes significantly to the understanding of mental health treatments, fostering ongoing dialogue and innovation in the discipline.

Annals of Clinical Psychiatry, published by QUADRANT HEALTHCOM INC, is a leading journal in the fields of Medicine and Psychiatry & Mental Health. With its longstanding commitment to advancing clinical knowledge since 1989, this esteemed journal contributes invaluable insights into current psychiatric practices and mental health research. The journal is recognized in the Scopus ranking with a position in the 34th percentile, reflective of its focused scope and substantial academic contributions. While access to the journal is tailored for professionals and researchers, the absence of Open Access highlights the journal's dedication to maintaining quality and rigorous peer-reviewed standards. As part of the Q3 quartile for both Medicine and Psychiatry categories in 2023, Annals of Clinical Psychiatry serves as an essential resource for those dedicated to improving mental health outcomes, making it a vital platform for practitioners, researchers, and students alike. Situated in Parsippany, New Jersey, the journal remains a pivotal entity that fosters scholarly dialogue and exploration in clinical psychiatry.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

ACTA PSYCHIATRICA SCANDINAVICA is a leading journal in the field of Psychiatry and Mental Health, published by Wiley since its inception in 1926. With a strong commitment to advancing psychiatric research, this esteemed journal boasts an impressive impact factor and ranks within the top 7% of its category, reflecting its influence and relevance in the field. Operating without an Open Access model, the journal serves as a vital resource for professionals, researchers, and students keen on accessing high-quality, peer-reviewed studies focused on mental health issues. The scope of ACTA PSYCHIATRICA SCANDINAVICA spans a broad spectrum of psychiatric topics, providing a platform for groundbreaking research and clinical practice insights. Based in the United Kingdom and featuring contributions from experts worldwide, the journal continues to shape the future of psychiatric research through its rigorous publication standards and commitment to scholarly excellence.

Welcome to the Journal of Behavior Therapy and Experimental Psychiatry, a distinguished publication in the field of psychological research, recognized for its commitment to advancing knowledge in behavior therapy and experimental psychiatry. Published by Pergamon-Elsevier Science Ltd in the United Kingdom, this journal plays a crucial role in disseminating innovative findings and theoretical advancements since its inception in 1970. With an impressive array of impact factors, this journal proudly holds a Q1 ranking in Arts and Humanities (miscellaneous) and Q2 rankings across Clinical Psychology, Experimental and Cognitive Psychology, and Psychiatry and Mental Health categories in 2023. The journal provides a platform for both established researchers and emerging scholars to share insights that enhance practice and inform policy in mental health. Although not an Open Access journal, it ensures broad accessibility to its content through institutional subscriptions and affiliations. By focusing on high-quality, rigorous research, the Journal of Behavior Therapy and Experimental Psychiatry continues to shape the understanding of behavioral interventions and their psychological implications, making it an indispensable resource for professionals and students alike.